SBRT for oligometastatic disease of mixed histologies has been shown to improve progression-free and even overall survival. A large cooperative group study recently demonstrated that there was no overall survival advantage seen when constrained to breast cancer alone. With improving systemic therapy options, appropriate patient selection may be key when using metastasis directed therapy. It is important to understand the options and application backed by evidence to date when treating oligometastatic and oligoprogressive breast cancer. 

This activity focuses on individualizing shared decision making between interdisciplinary teams and the patient. In a climate of rapidly changing systemic therapy, prolonged survival with metastatic disease, and conflicting messages from the literature, presenters help oncology teams understand the evidence to date and help demonstrate a variety of ways to apply new therapies for this patient population. Presenters discuss the data known to date and discuss application to varied cases. With radiation oncology and medical oncology presenting, different perspectives are shared when considering patient selection, therapeutic options, and sequencing of treatments for denovo oligometastatic, oligoprogressive, and oligopersistent disease. After presenters have completed, there is time for case discussions and/or panel Q&A. 

Topics:

1. Oligometastatic Breast Cancer: Systemic Therapy Considerations
   Jairam Krishnamurthy, MD, FACP
2. Oligometastatic Breast Cancer: Patient Selection for Metastasis Directed Therapy 
   Steven J. Chmura, MD, PhD
3. A Primer on How-To: Spinal SBRT
   Asal Shoushtari Rahimi, MD, MS
4. Q and A
   Full Panel

This activity is available from May 28, 2024, through 11:59 p.m. Eastern time on May 27, 2026. 

This activity was originally recorded at the 2023 ASTRO Annual Meeting.